Section Arrow
Quote
PRAX.NASDAQ
- Praxis Precision Medicines
Quotes are at least 15-min delayed:2026/07/23 05:17 EDT
Pre Market
Last
 310.01
-2.09 (-0.67%)
Bid
300
Ask
351
High 312.11 
Low 309.01 
Volume 103 
Regular Hours (Closed)
Last
 312.1
-5.77 (-1.82%)
Day High 
317.45 
Prev. Close
317.87 
1-M High
354.165 
Volume 
229.41K 
Bid
300
Ask
351
Day Low
308.06 
Open
311.52 
1-M Low
285 
Market Cap 
8.86B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 319.67 
20-SMA 321.38 
50-SMA 311.52 
52-W High 366.52 
52-W Low 37.19 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-13.39/-8.52
Enterprise Value
8.86B
Balance Sheet
Book Value Per Share
50.57
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.07
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LABTLakewood-Amedex Biotherapeutics Inc3.41+1.55+83.33%-- 
Pre Market 3.02 -0.39 -11.44%
KAPAKairos Pharma Ltd.0.3127-0.0453-12.65%-- 
Pre Market 0.2918 -0.0209 -6.68%
JUNSJupiter Neurosciences Inc0.1746+0.0049+2.89%-- 
Pre Market 0.1666 -0.008 -4.58%
GOSSGossamer Bio0.1446-0.0102-6.59%-- 
Pre Market 0.1453 +0.0007 +0.48%
RXRXRecursion Pharmaceuticals2.98-0.1-3.25%-- 
Pre Market 3.0095 +0.0295 +0.99%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.